Eris Lifesciences Ltd (IN:ERIS)
:ERIS
Want to see IN:ERIS full AI Analyst Report?
ERIS Stock Chart & Stats
₹1530.85
₹7.70(0.59%)
At close: 4:00 PM EST
₹1530.85
₹7.70(0.59%)
Day’s Range― - ―
52-Week Range₹1,237.90 - ₹1,909.55
Previous CloseN/A
Volume91.31K
Average Volume (3M)2.07K
Market Cap
₹202.24B
Enterprise Value₹214.95B
Total Cash (Recent Filing)₹839.20M
Total Debt (Recent Filing)₹23.89B
Price to Earnings (P/E)28.6
Beta0.61
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.47%
Share Statistics
EPS (TTM)30.53
Shares Outstanding138,567,260
10 Day Avg. Volume1,915
30 Day Avg. Volume2,071
Financial Highlights & Ratios
PEG Ratio-5.23
Price to Book (P/B)6.64
Price to Sales (P/S)6.58
P/FCF Ratio20.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)54.35
Revenue Forecast (FY)₹37.54B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue And Cash GrowthFundamentals show durable top-line and operating cash expansion (Fundamentals: RevenueGrowth 12.37%, EPS growth 30.97%). Consistent revenue and operating cash growth supports reinvestment, funds marketing/field force expansion, and underpins medium-term margin stability and strategic optionality.
Branded Chronic-therapy FocusA portfolio concentrated in chronic and lifestyle therapies creates recurring demand and sticky prescribing behavior. The physician-focused marketing model builds brand loyalty and revenue defensibility, supporting repeat sales, predictable demand, and more efficient long-term marketing ROI versus one-off acute therapies.
Strong Margins And Efficient OperationsRobust gross and EBITDA margins, coupled with a strong Return on Equity, indicate efficient cost management and profitable branded pricing. Durable margin structure enhances cash generation, funds R&D/marketing, and provides buffers against pricing or input-cost pressure over the medium term.
Bears Say
Cash Balance Decline & FCF VolatilityA falling cash balance and variable free cash flow reduce predictability for capex, dividends, or inorganic moves. Volatile FCF can constrain strategic flexibility, force cautious capital allocation, and increase refinancing risk if adverse conditions persist over upcoming quarters.
Concentration In Domestic Physician-driven SalesHeavy reliance on the domestic Indian prescription channel concentrates revenue risk to local regulatory, pricing, and reimbursement changes. Limited geographic diversification means adverse policy or demand shifts in India would materially impact sales and growth visibility over the medium term.
Reliance On Contract ManufacturingDependence on third-party manufacturers exposes the company to supply, quality, and capacity constraints beyond its direct control. Such outsourcing can create durable operational risks and margin pressure during supply disruptions or input-cost shifts, affecting product availability and growth execution.
Eris Lifesciences Ltd News
ERIS FAQ
What was Eris Lifesciences Ltd’s price range in the past 12 months?
Eris Lifesciences Ltd lowest stock price was ₹1237.90 and its highest was ₹1909.55 in the past 12 months.
What is Eris Lifesciences Ltd’s market cap?
Eris Lifesciences Ltd’s market cap is ₹202.24B.
When is Eris Lifesciences Ltd’s upcoming earnings report date?
Eris Lifesciences Ltd’s upcoming earnings report date is Jul 31, 2026 which is in 70 days.
How were Eris Lifesciences Ltd’s earnings last quarter?
Eris Lifesciences Ltd released its earnings results on May 20, 2026. The company reported ₹9.55 earnings per share for the quarter, beating the consensus estimate of ₹9.425 by ₹0.125.
Is Eris Lifesciences Ltd overvalued?
According to Wall Street analysts Eris Lifesciences Ltd’s price is currently Overvalued.
Does Eris Lifesciences Ltd pay dividends?
Eris Lifesciences Ltd pays a Annually dividend of ₹7.35 which represents an annual dividend yield of 0.47%. See more information on Eris Lifesciences Ltd dividends here
What is Eris Lifesciences Ltd’s EPS estimate?
Eris Lifesciences Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eris Lifesciences Ltd have?
Eris Lifesciences Ltd has 138,567,260 shares outstanding.
What happened to Eris Lifesciences Ltd’s price movement after its last earnings report?
Eris Lifesciences Ltd reported an EPS of ₹9.55 in its last earnings report, beating expectations of ₹9.425. Following the earnings report the stock price went up 9.134%.
Which hedge fund is a major shareholder of Eris Lifesciences Ltd?
Currently, no hedge funds are holding shares in IN:ERIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eris Lifesciences Ltd
Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.
Technical Analysis
Emcure Pharmaceuticals Limited
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Sanofi Consumer Healthcare India Limited
―